2014 Press Releases

Press Releases | In the News

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle
09/08/14Novan’s Nitric Oxide Drug Candidate Inhibits Growth of Papillomavirus in Translational Animal Model
Topical Anti-Viral Could Lead to Treatment for HPV Infections and Help Prevent CancerData Presented at 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy, Taking Place in Washington, DC, September 5-9, 2014DURHAM, N.C.--(September 8, 2014)--Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced today that Novan’s nitric oxide drug candidate SB206 was shown to inhibit papilloma growth in a preclinical animal study. About two-... 
08/19/14Novan’s Nitricil™ Technology Shows Efficacy Against Multidrug Resistant Superbugs
Comparative Effectiveness Data in Preclinical In Vivo Models to be Presented at the 2014 Military Health System Research SymposiumDURHAM, N.C.-August 19, 2014-Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced today that the Company’s Nitricil™ platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe. The antimicrobi... 
08/14/14Novan to Present Antiviral Preclinical Results of Nitric Oxide-Releasing Drug Candidates for the Treatment of Papillomavirus
Abstract Accepted for Presentation at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy September 8, 2014DURHAM, N.C. (August 14, 2014) - Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, announced today that antiviral data from a preclinical animal study has been accepted for presentation at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 5-9, 2014, in Washington, DC... 
06/19/14Novan Therapeutics' Pipeline Fueled by Public-Private Partnerships Receives National Recognition
2014 Tibbetts Award Winner for Excellence in Small Business Innovation Research BIO International Convention "Buzz of BIO" Pipeline of Promise WinnerDURHAM, NC (June 19, 2014) – Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today that the U.S. Small Business Administration recently named the Company a 2014 Tibbetts Award winner. The Tibbetts Awards are presented annually to those companies and individuals th... 
04/23/14Novan Therapeutics' Abstract Accepted for Poster Session at 2014 Society for Investigative Dermatology Annual Meeting
Company to Present Poster on Phase 2 Study Results of Lead Product Candidate SB204 for the Treatment of Acne Vulgaris on May 8, 2014DURHAM, NC (April 23, 2014) – Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced that data from the Phase 2 clinical trial in acne vulgaris with its lead product candidate, SB204, has been accepted for presentation at the 2014 Annual Meeting of the Society for Investigative Dermatolo... 
03/19/14Novan Announces Positive Phase 2 Results for Novel Acne Treatment
SB204 Shows Statistically Significant Results in Only 4 WeeksDurham, NC (March 19, 2014) – Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. Acne is a skin disease that affects more than fifty million people in the United States. The Phase 2 study was a double blind, vehicle-controlled, dose-ranging study...